FIRRM and ovarian cancer: As shown in Figure 1D, significantly elevated C1ORF112 expression was observed in most cancer types, including bladder cancer, brain and central nervous system cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, lung cancer, lymphoma, ovarian cancer, and sarcoma.